



Next Generation Networks In Neuroscience- NeuroNex 2019

Frequently Asked Questions.

This FAQ document is for UK applicants wishing to apply to the ‘NeuroNex 2019’ research call. This guidance complements the Webinar which took place on 5th April 2019, a recording of this can be found in full on the [NeuroNex webpage here](#).

Contents

1. Is it possible to include investigators outside of the 4 partner countries?	2
2. Can the UK fund studentships as part of the projects?	2
3. Do UK components require a clear medical or translational angle?	2
4. Will the 3-year length of UK grants affect the application?	2
5. Will smaller networks be viewed differently to larger ones?	3
6. Can the Network lead be based only partially in the US?	3
7. Should preliminary proposals be written with input from all participants?	3
8. How will preliminary proposals be reviewed and decisions for full submissions made?	3



1. Is it possible to include investigators outside of the 4 partner countries?

For UK-based components of IRGs, inclusion of overseas CoIs is permitted but must adhere to MRC standard rules. Section 3.3 of MRC Guidance for Applicants states:

Overseas costs may not include:

- Overheads (estate or indirect costs) for an overseas CoI, or any locally employed staff in a developed country.
- Overseas project partners costs – this may apply, for example, where a project partner provides guidance/advice in return for receipt of research benefit but where intellectual input is not sufficient for CoI status.

2. Can the UK fund studentships as part of the projects?

No, the MRC standard rules for studentships applies for this call. UK studentships are not eligible for funding through this call and must not be included. However, UK components of IRGs can request travel funds for existing students to travel to international labs within the Network for training opportunities.

3. Do UK components require a clear medical or translational angle?

Yes, all UK components of IRGs must adhere to MRC remit. MRC supports research relevant to human health and disease – from fundamental discovery science in non-clinical, clinical, and population settings, through to development and initial testing of new treatments or preventive measures – and focuses on the areas of fundamental science most important for health.

4. Will the 3-year length of UK grants affect the application?

Networks and their associated IRGs will not be treated any differently during review or panel



meetings based on the inclusion of 3-year UK proposals vs 5-year proposals from other funders.

5. Will smaller networks be viewed differently to larger ones?

No, as long as the Network's overarching questions are adequately covered through the component projects and IRGs, any Networks within the specified guidelines (Networks comprise 2-4 IRGs, each made up of 3-6 investigators) will be treated equally.

6. Can the Network lead be based only partially in the US?

Yes, as long as the lead US PI is affiliated with an eligible RO in the US, they may also hold posts in other countries.

7. Should preliminary proposals be written with input from all participants?

Yes, all components of IRGs should submit their own proposals to the lead US PI, to be submitted as a single outline through the US FastLane system.

8. How will preliminary proposals be reviewed and decisions for full submissions made?

Preliminary proposals will be reviewed by panels comprised of experts provided by all participating funding bodies. This meeting will take place in September 2019 and applicants notified of outcome shortly after.